PLx Pharma Inc.
PLXP · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.10 | 0.00 | -0.14 |
| FCF Yield | -16.95% | -23.02% | -33.11% | -75.99% |
| EV / EBITDA | -3.41 | -2.36 | -2.12 | 2.81 |
| Quality | ||||
| ROIC | -70.27% | -56.40% | -92.00% | -66.17% |
| Gross Margin | 41.46% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.70 | 0.80 | 0.62 | -10.60 |
| Growth | ||||
| Revenue 3-Year CAGR | 143.94% | -65.69% | -10.12% | – |
| Free Cash Flow Growth | -160.16% | 4.30% | -27.05% | 26.65% |
| Safety | ||||
| Net Debt / EBITDA | 1.97 | 1.62 | 0.70 | -3.15 |
| Interest Coverage | -40,790.00 | -43.71 | -14.27 | -9.57 |
| Efficiency | ||||
| Inventory Turnover | 1.95 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -590.29 | 0.00 | 12.06 | 8.84 |